A first-in-class dual CD28/ICOS antagonist
ALPN-101 is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways being developed for treatment of severe inflammatory diseases. Leveraging our proprietary scientific platform, our scientists engineered a single protein domain, or vIgD (Variant Ig Domain) based on human inducible T cell costimulator ligand (ICOSL) that is capable of binding to both CD28 and ICOS. By simultaneously blocking two key costimulatory pathways, ALPN-101 has the potential to improve outcomes in patients suffering from severe autoimmune/inflammatory disease.
In June 2020, we signed an exclusive worldwide option and license agreement with AbbVie for ALPN-101. Under the terms of the agreement, we received an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.
ALPN-101 completed enrollment of a Phase 1 healthy volunteer study in October 2019. Final data were presented at the 2020 EULAR E-Congress. The key findings presented are summarized below:
- No infusion-related, hypersensitivity, or allergic reactions
- No cytokine storm or release (CytokineMAP A&B)
- No grade 3+ adverse events
- Most common adverse events were self-limited upper respiratory tract infections and headaches
ALPN-101 is currently enrolling Synergy, a Phase 2 study of ALPN-101 in patients with Systemic Lupus Erythematosus (SLE). For more information on our ongoing clinical trials please refer to the Clinical Trials portion of our website.